Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEBBLES trial of EpiCeram for eczema and food allergy prevention in high-risk infants
ACTRN12617001380381Phase 3Active, not recruiting
- Sponsor
- University of Melbourne
- Start
- Mar 2018
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of EpiCeram in atopic dermatitis (AD) and food allergy (2 arms), sponsored by University of Melbourne. Primary endpoints: Presence of eczema and Confirmed food allergy. Started Mar 2018; status: active, not recruiting.
02
Drugs
EpiCeram
03
Conditions
atopic dermatitis (AD)food allergy
Beyond the preview
Go deeper on ACTRN12617001380381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001380381.